RUA Life Sciences has published a trading update for the 6-month period to March 2026 (1H26). The company expects to deliver revenue growth of 6% YoY to £2.8m, supported by strong growth from the UK CDMO operation and Biomaterials licensing, offset by Abiss revenues, as previously announced. Gross margin is expected to be 75% (1H25A: 74%) and the company expects to break even at the adjusted EBITDA level, reflecting continued cost control. As announced on 12 May 2026, RUA Structural Heart has fi ....
